Biotech Values

[mcbio]

Wheeler should be rated based on how he delivers to shareholders.

I strongly disagree with this notion. Wheeler can't control how the market reacts to his and MNTA's accomplishments. How can he control the the market's reaction to the perceived Teva threat with generic Lovenox and whether or not the market views MNTA's own success with generic Lovenox as validation for its platform (I'd argue it hasn't)? Wheeler has delivered as far as I am concerned. Now it's just a question to me of at what point will the market give MNTA more credit for its existing accomplishments to date and its potential prospects to come. I'm content to continue to hold MNTA until I feel we've reached that point. Perhaps it will take success on the generic Copaxone front or the FoB front, but I am willing to hold.